Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06745999 · ClinicalTrials.gov registry record · Phase 4

Cryotherapy in Combination with Red Light PDT for Actinic Keratosis of Full Face

A Phase 4 study of Actinic Keratoses, sponsored by Psoriasis Treatment Center of Central New Jersey.

Recruiting
Registry status
Phase 4
Development phase
40
Enrollment target
1
Study location

NCT06745999 is a Phase 4 study of Actinic Keratoses that is actively recruiting participants, run by Psoriasis Treatment Center of Central New Jersey. The registered enrollment target is 40 participants, below the 95-participant average among 12 other Actinic Keratoses trials with a reported enrollment target (58% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06745999, a Phase 4 study of Actinic Keratoses, is actively recruiting participants, sponsored by Psoriasis Treatment Center of Central New Jersey.

RECRUITING
Registry status
Phase 4
Development phase
40 participants
Enrollment target
1
Study location

Study Summary

40 patients randomized 1:1 to receive cryotherapy followed by 10% ALA gel Red light PDT vs. to 10% ALA gel Red Light PDT followed by cryotherapy.

Conditions Studied

Interventions

  • DRUG Ameluz 10% Topical Gel
  • DEVICE Red Light PDT
  • PROCEDURE Cryotherapy

Study Locations (1)

New Jersey

  • Psoriasis Treatment Center of New Jersey - East Windsor

Trial Details

FieldValue
Enrollment Target 40 participants
Start Date 2023-05-03
Est. Completion 2025-06
Phase Phase 4

What the Registry Record Tells You About NCT06745999

The ClinicalTrials.gov registry entry for NCT06745999 describes a study currently listed as recruiting, categorized as Phase 4. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 95-participant average among 12 other Actinic Keratoses trials with a reported enrollment target (58% lower). The listed sponsor is Psoriasis Treatment Center of Central New Jersey, which has 16 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Actinic Keratoses appearing as the primary indexed condition, and to 3 interventions - of which Ameluz 10% Topical Gel is the first listed.

NCT06745999 reports 1 study location spanning 1 distinct geographic area - top geographies include New Jersey.

Frequently Asked Questions

What is clinical trial NCT06745999 about?

NCT06745999 is a clinical study titled "Cryotherapy in Combination with Red Light PDT for Actinic Keratosis of Full Face". 40 patients randomized 1:1 to receive cryotherapy followed by 10% ALA gel Red light PDT vs. to 10% ALA gel Red Light PDT followed by cryotherapy.

What is the current status of trial NCT06745999?

This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 40 participants. The study started on 2023-05-03. Estimated completion is 2025-06.

What conditions does trial NCT06745999 study?

This clinical trial studies the following conditions: Actinic Keratoses.

What interventions are being tested in trial NCT06745999?

The interventions under investigation include: Ameluz 10% Topical Gel (DRUG), Red Light PDT (DEVICE), Cryotherapy (PROCEDURE).

Who is sponsoring clinical trial NCT06745999?

This trial is sponsored by Psoriasis Treatment Center of Central New Jersey, which has 16 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06745999 being conducted?

This trial has 1 study location across New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Actinic Keratoses

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.